1932

Abstract

Long-term control of viral outbreaks requires the use of vaccines to impart acquired resistance and ensuing protection. In the wake of an epidemic, established immunity against a particular disease can limit spread and significantly decrease mortality. Creation of a safe and efficacious vaccine against Ebola virus (EBOV) has proven elusive so far, but various inventive strategies are now being employed to counteract the threat of outbreaks caused by EBOV and related filoviruses. Here, we present a current overview of progress in the field of Ebola virus vaccine development.

Keyword(s): EBOV vaccineimmunizationvector
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-051215-030919
2017-01-14
2024-06-19
Loading full text...

Full text loading...

/deliver/fulltext/med/68/1/annurev-med-051215-030919.html?itemId=/content/journals/10.1146/annurev-med-051215-030919&mimeType=html&fmt=ahah

Literature Cited

  1. Kuhn JH, Andersen KG, Bao Y. 1.  et al. 2014. Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses 6:3663–82 [Google Scholar]
  2. 2. Centers for Disease Control and Prevention 2016. Outbreaks chronology: Ebola virus disease 31 Mar. http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html [Google Scholar]
  3. 3. Centers for Disease Control and Prevention 2014. Chronology of Marburg hemorrhagic fever outbreaks 9 Oct. http://www.cdc.gov/vhf/marburg/resources/outbreak-table.html [Google Scholar]
  4. Maruyama J, Miyamoto H, Kajihara M. 4.  et al. 2014. Characterization of the envelope glycoprotein of a novel filovirus, Lloviu virus. J. Virol. 88:99–109 [Google Scholar]
  5. Negredo A, Palacios G, Vazquez-Moron S. 5.  et al. 2011. Discovery of an ebolavirus-like filovirus in Europe. PLOS Pathog. 7:e1002304 [Google Scholar]
  6. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. 6.  2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7:393–400 [Google Scholar]
  7. Bente D, Gren J, Strong JE, Feldmann H. 7.  2009. Disease modeling for Ebola and Marburg viruses. Dis. Model. Mech. 2:12–17 [Google Scholar]
  8. Bray M, Davis K, Geisbert T. 8.  et al. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651–61 [Google Scholar]
  9. Connolly BM, Steele KE, Davis KJ. 9.  et al. 1999. Pathogenesis of experimental Ebola virus infection in guinea pigs. J. Infect. Dis. 179:Suppl. 1S203–17 [Google Scholar]
  10. Wong G, Qiu X, Richardson JS. 10.  et al. 2015. Ebola virus transmission in guinea pigs. J. Virol. 89:1314–23 [Google Scholar]
  11. van Griensven J, Edwards T, de Lamballerie X. 11.  et al. 2016. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N. Engl. J. Med. 374:33–42 [Google Scholar]
  12. Qiu X, Wong G, Audet J. 12.  et al. 2014. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514:47–53 [Google Scholar]
  13. 13. World Health Organization (WHO) 2015. Ebola vaccines, therapies, and diagnostics 21 Nov. http://www.who.int/medicines/emp_ebola_q_as/en/ [Google Scholar]
  14. Riemenschneider J, Garrison A, Geisbert J. 14.  et al. 2003. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21:4071–80 [Google Scholar]
  15. Lu S, Wang S, Grimes-Serrano JM. 15.  2008. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 7:175–91 [Google Scholar]
  16. Shedlock DJ, Aviles J, Talbott KT. 16.  et al. 2013. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol. Ther. 21:1432–44 [Google Scholar]
  17. Sullivan NJ, Sanchez A, Rollin PE. 17.  et al. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605–9 [Google Scholar]
  18. Hensley LE, Mulangu S, Asiedu C. 18.  et al. 2010. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLOS Pathog. 6:e1000904 [Google Scholar]
  19. Kibuuka H, Berkowitz NM, Millard M. 19.  et al. 2014. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet 385:1545–54 [Google Scholar]
  20. 20. National Institute of Allergy and Infectious Diseases (NIAID) 2016. Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda 4 Apr. https://clinicaltrials.gov/ct2/show/NCT02354404 [Google Scholar]
  21. 21. Inovio Pharmaceuticals 2016. INO-4212 SynCon® vaccine and dMAb targeting Ebola http://www.inovio.com/products/infectious-disease-vaccines/ebola/ [Google Scholar]
  22. 22. Inovio Pharmaceuticals 2015. Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers 16 Oct. https://clinicaltrials.gov/ct2/show/study/NCT02464670 [Google Scholar]
  23. Sridhar S. 23.  2015. Clinical development of Ebola vaccines. Adv. Vaccines 3:125–38 [Google Scholar]
  24. Halstead SB, Thomas SJ. 24.  2011. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev. Vaccines 10:355–64 [Google Scholar]
  25. McElroy AK, Akondy RS, Davis CW. 25.  et al. 2015. Human Ebola virus infection results in substantial immune activation. PNAS 112:4719–24 [Google Scholar]
  26. Warfield KL, Bosio CM, Welcher BC. 26.  et al. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. PNAS 100:15889–94 [Google Scholar]
  27. Warfield KL, Aman MJ. 27.  2011. Advances in virus-like particle vaccines for filoviruses. J. Infect. Dis. 204:Suppl. 3S1053–59 [Google Scholar]
  28. Garbutt M, Liebscher R, Wahl-Jensen V. 52.  et al. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78:5458–65 [Google Scholar]
  29. Warfield KL, Dye JM, Wells JB. 28.  et al. 2015. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles. PLOS ONE 10:e0118881 [Google Scholar]
  30. Swenson DL, Warfield KL, Negley DL. 29.  et al. 2005. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23:3033–42 [Google Scholar]
  31. 30. Novavax 2016. Matrix-Madjuvant technology http://novavax.com/page/10/matrix-m-adjuvant-technology [Google Scholar]
  32. Bengtsson KL, Song H, Stertman L. 31.  et al. 2016. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine 34:1927–35 [Google Scholar]
  33. 32. Novavax 2015. Novavax Ebola/Makona glycoprotein (GP) nanoparticle vaccine candidate update: NHP and clinical data 21 Jul. http://novavax.com/download/files/presentations/Novavax_EBOV_GP_Vaccine_2015_07_21_FINAL.pdf [Google Scholar]
  34. Halfmann P, Ebihara H, Marzi A. 34.  et al. 2009. Replication-deficient Ebolavirus as a vaccine candidate. J. Virol. 83:3810–15 [Google Scholar]
  35. Jones SM, Feldmann H, Stroher U. 56.  et al. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786–90 [Google Scholar]
  36. Marzi A, Feldmann H. 33.  2014. Ebola virus vaccines: an overview of current approaches. Expert Rev. Vaccines 13:521–31 [Google Scholar]
  37. Marzi A, Halfmann P, Hill-Batorski L. 35.  et al. 2015. Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science 348:439–42 [Google Scholar]
  38. Geisbert TW, Bailey M, Hensley L. 36.  et al. 2011. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against Ebolavirus challenge. J. Virol. 85:4222–33 [Google Scholar]
  39. Wu XX, Yao HP, Wu NP. 37.  et al. 2015. Ebolavirus vaccines: progress in the fight against Ebola virus disease. Cell Physiol. Biochem. 37:1641–58 [Google Scholar]
  40. Van Hoof J. 38.  2015. Review of Ebola vaccines in Phase 1 clinical evaluation. Janssen Ebola vaccine emergency track program. Presented at WHO Meet., 8 Jan., Geneva, Switz. http://www.who.int/mediacentre/events/2015/S2.1_Janssen_ZEBOV_vaccine-Revised.pdf [Google Scholar]
  41. 39. EBOVAC 2 Consortium 2016. 1st EBOVAC2 e-newsletter Mar. http://www.ebovac2.com/images/EBOVAC2_newsletter_no._1_March_2016.pdf [Google Scholar]
  42. Ledgerwood JE, DeZure AD, Stanley DA. 40.  et al. 2014. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N. Engl. J. Med. doi: 10.1056/NEJMoa1410863 [Google Scholar]
  43. Berger O. 41.  2015. GSK/NIH Ebola vaccine development, GlaxoSmithKline VRBPAC, 12 May. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM448003.pdf [Google Scholar]
  44. Rampling T, Ewer K, Bowyer G. 42.  et al. 2015. A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report. N. Engl. J. Med. 374:1635–46 [Google Scholar]
  45. Zhang Q, Seto D. 43.  2015. Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N. Engl. J. Med. 373:775–76 [Google Scholar]
  46. De Santis O, Audran R, Pothin E. 44.  et al. 2016. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, Phase 1/2a study. Lancet Infect. Dis. 16:311–20 [Google Scholar]
  47. Tapia MD, Sow SO, Lyke KE. 45.  et al. 2016. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a Phase 1, single-blind, randomised trial, a Phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet. Infect. Dis. 16:31–42 [Google Scholar]
  48. 46. GlaxoSmithKline 2016. A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults 10 Mar. https://clinicaltrials.gov/ct2/show/NCT02485301?term=GSK±ebola&rank=2 [Google Scholar]
  49. 47. GlaxoSmithKline 2016. A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children 21 Jan. https://clinicaltrials.gov/ct2/show/NCT02548078?term=GSK±ebola&rank=1 [Google Scholar]
  50. 48. Pharmaceutical Research and Manufacturers of America (PhRMA) 2015. Ebola: the biopharmaceutical industry remains committed to developing medical advances 15 Oct. http://www.phrma.org/sites/default/files/pdf/ebola-backgrounder.pdf [Google Scholar]
  51. Kennedy SB, Neaton JD, Lane HC. 49.  et al. 2016. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin. Trials 13:49–56 [Google Scholar]
  52. Paris R, Kuschner RA, Binn L. 50.  et al. 2014. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin. Vaccine Immunol. 21:783–86 [Google Scholar]
  53. Lawson ND, Stillman EA, Whitt MA, Rose JK. 51.  1995. Recombinant vesicular stomatitis viruses from DNA. PNAS 92:4477–81 [Google Scholar]
  54. Jones SM, Stroher U, Fernando L. 53.  et al. 2007. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J. Infect. Dis. 196:Suppl. 2S404–12 [Google Scholar]
  55. Marzi A, Ebihara H, Callison J. 54.  et al. 2011. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J. Infect. Dis. 204:Suppl. 3S1066–74 [Google Scholar]
  56. Tsuda Y, Safronetz D, Brown K. 55.  et al. 2011. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J. Infect. Dis. 204:Suppl. 3S1090–97 [Google Scholar]
  57. Marzi A, Feldmann H, Geisbert TW, Falzarano D. 57.  2011. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J. Bioterror Biodef. S1:4 pii:2157–2526-S1-004 [Google Scholar]
  58. Geisbert TW, Geisbert JB, Leung A. 58.  et al. 2009. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J. Virol. 83:7296–304 [Google Scholar]
  59. Geisbert TW, Daddario-Dicaprio KM, Lewis MG. 59.  et al. 2008. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLOS Pathog. 4:e1000225 [Google Scholar]
  60. Agnandji ST, Huttner A, Zinser ME. 60.  et al. 2015. Phase 1 trials of rVSV ebola vaccine in Africa and Europe—preliminary report. N. Engl. J. Med. 374:1647–60 [Google Scholar]
  61. Marzi A, Engelmann F, Feldmann F. 61.  et al. 2013. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. PNAS 110:1893–98 [Google Scholar]
  62. Henao-Restrepo AM, Longini IM, Egger M. 62.  et al. 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386:857–66 [Google Scholar]
  63. Kucharski AJ, Eggo RM, Watson CH. 63.  et al. 2016. Effectiveness of ring vaccination as control strategy for Ebola virus disease. Emerg. Infect. Dis. 22:105–8 [Google Scholar]
  64. Geisbert TW, Daddario-DiCaprio KM, Williams KJ. 64.  et al. 2008. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 82:5664–68 [Google Scholar]
  65. Lai L, Davey R, Beck A. 65.  et al. 2015. Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. JAMA 313:1249–55 [Google Scholar]
  66. Schnell MJ, Mebatsion T, Conzelmann KK. 66.  1994. Infectious rabies viruses from cloned cDNA. EMBO J 13:4195–203 [Google Scholar]
  67. Bukreyev A, Skiadopoulos MH, Murphy BR, Collins PL. 67.  2006. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 80:10293–306 [Google Scholar]
  68. Blaney JE, Wirblich C, Papaneri AB. 68.  et al. 2011. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J. Virol. 85:10605–16 [Google Scholar]
  69. Blaney JE, Marzi A, Willet M. 69.  et al. 2013. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLOS Pathog 9:e1003389 [Google Scholar]
  70. Mebatsion T, Schnell MJ, Cox JH. 70.  et al. 1996. Highly stable expression of a foreign gene from rabies virus vectors. PNAS 93:7310–14 [Google Scholar]
  71. Willet M, Kurup D, Papaneri A. 71.  et al. 2015. Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses. J. Infect. Dis. 212:Suppl. 2S414–24 [Google Scholar]
  72. Currie J, Grenfell B, Farrar J. 72.  2016. Infectious diseases. Beyond Ebola. Science 351:815–16 [Google Scholar]
/content/journals/10.1146/annurev-med-051215-030919
Loading
/content/journals/10.1146/annurev-med-051215-030919
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error